RLAY

Relay Therapeutics Inc

Add to Watchlist

Advanced Chart

3.100

-0.160(-4.910%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.330

Open

3.330

VWAP

3.14

Vol

1.54M

Mkt Cap

528.52M

Low

3.035

Amount

4.85M

EV/EBITDA(TTM)

Total Shares

132.74M

-225.53M

EV/OCF(TTM)

P/S(TTM)

46.54

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

-0.506

-19.7%

-0.466

-32.49%

-0.480

-22.64%

Estimates Revision

The market is revising Downward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by -1.7% over the past three months. During the same period, the stock price has changed by -31.72%.

Revenue Estimates for FY2025

Revise Downward

-1.7%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.57%

In Past 3 Month

Stock Price

Go Down

-31.72%

In Past 3 Month

10 Analyst Rating

396.13% Upside

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.38 USD with a low forecast of 4.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

396.13% Upside

Current: 3.100

Low

4.00

Averages

15.38

High

23.00

396.13% Upside

Current: 3.100

Low

4.00

Averages

15.38

High

23.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$16

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$16

2025-03-07

Reiterates

Strong Buy

Reason

Stifel

Bradley Canino

Strong Buy

Maintains

$27 → $23

2025-02-27

Reason

Stifel

Bradley Canino

Price Target

$27 → $23

2025-02-27

Maintains

Strong Buy

Reason

Goldman Sachs

Salveen Richter

Strong Buy

Maintains

$20 → $18

2025-02-27

Reason

Goldman Sachs

Salveen Richter

Price Target

$20 → $18

2025-02-27

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$16

2025-01-14

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$16

2025-01-14

Reiterates

Strong Buy

Reason

JMP Securities

Silvan Tuerkcan

Buy

Reiterates

$21

2024-12-12

Reason

JMP Securities

Silvan Tuerkcan

Price Target

$21

2024-12-12

Reiterates

Buy

Reason

Leerink Partners

Christopher Liu

Buy

Maintains

$19 → $18

2024-12-04

Reason

Leerink Partners

Christopher Liu

Price Target

$19 → $18

2024-12-04

Maintains

Buy

Reason

Leerink analyst Christopher Liu lowered the firm's price target on Relay Therapeutics to $18 from $19 and keeps an Outperform rating on the shares after the company announced that lirafugratinib will be out licensed to Elevar Therapeutics. Recall, the company had previously announced its decision to seek a global commercial partner for lirafugratinib during a company event in September 2024. Overall, Leerink thinks this decision is a prudent use of resources given the relatively small size of FGFR2+ populations.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is -1.62, compared to its 5-year average forward P/E of -9.04. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.04

Current PE

-1.62

Overvalued PE

0.06

Undervalued PE

-18.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.25

Current EV/EBITDA

0.47

Overvalued EV/EBITDA

1.71

Undervalued EV/EBITDA

-14.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

962.43

Current PS

142.94

Overvalued PS

2245.59

Undervalued PS

-320.72

Financials

Annual

Quarterly

FY2024Q4

0.00

Total Revenue

FY2024Q4

YoY :

-9.85%

-84.98M

Operating Profit

FY2024Q4

-76.00M

Net Income after Tax

FY2024Q4

YoY :

-32.84%

-0.45

EPS - Diluted

FY2024Q4

YoY :

-35.20%

-57.87M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

+110.57%

-2.51K

FCF Margin - %

FY2024Q4

YoY :

+152.10%

-3.37K

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 904.48% over the last month.

Sold

0-3

Months

200.6K

USD

3-6

Months

4.5M

USD

6-9

Months

148.0K

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.2M

Volume

6-9

Months

0.0

Volume

0-12

Months

1.5M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.5M

Volume

Months

6-9

0.0

Volume

Months

0-12

4.7M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 904.48% over the last month.

Sold

0-3

Months

200.6K

USD

3-6

Months

4.5M

USD

6-9

Months

148.0K

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RLAY News & Events

Events Timeline

2025-02-26 (ET)

2025-02-26

16:33:11

Relay Therapeutics reports Q4 EPS (45c), consensus (55c)

2025-01-11 (ET)

2025-01-11

13:22:27

Potential acquisition of Scorpion positive for Relay, says Barclays

2024-12-11 (ET)

2024-12-11

05:07:38

Relay Therapeutics reports updated interim clinical data for RLY-2608

News

9.5

04-28Newsfilter

PinnedRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

4.0

04-17Benzinga

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

5.0

04-09Newsfilter

Barbara Weber, M.D., Elected to ITM Supervisory Board

People Also Watch

MeiraGTx Holdings PLC

Rayonier Advanced Materials Inc

Lincoln Educational Services Corp

Gladstone Investment Corp

Peoples Financial Services Corp

Greenlight Capital Re Ltd

Flushing Financial Corp

12.450

USD

+0.81%

FAQ

What is Relay Therapeutics Inc (RLAY) stock price today?

The current price of RLAY is 3.1 USD — it has decreased -4.91 % in the last trading day.

RLAY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

RLAY News & Events

Events Timeline

News

People Also Watch

FAQ

What is Relay Therapeutics Inc (RLAY) stock price today?

What is Relay Therapeutics Inc (RLAY)'s business?

What is the price predicton of RLAY Stock?

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Relay Therapeutics Inc (RLAY)'s fundamentals?

How many employees does Relay Therapeutics Inc (RLAY). have?

What is Relay Therapeutics Inc (RLAY) market cap?